Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 15;306(12):F1499-506.
doi: 10.1152/ajprenal.00058.2014. Epub 2014 Apr 23.

NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease

Jennifer J DuPont  1 , Meghan G Ramick  1 , William B Farquhar  2 , Raymond R Townsend  3 , David G Edwards  4
Affiliations

NADPH oxidase-derived reactive oxygen species contribute to impaired cutaneous microvascular function in chronic kidney disease

Jennifer J DuPont et al. Am J Physiol Renal Physiol. .

Abstract

Oxidative stress promotes vascular dysfunction in chronic kidney disease (CKD). We utilized the cutaneous circulation to test the hypothesis that reactive oxygen species derived from NADPH oxidase and xanthine oxidase impair nitric oxide (NO)-dependent cutaneous vasodilation in CKD. Twenty subjects, 10 stage 3 and 4 patients with CKD (61 ± 4 yr; 5 men/5 women; eGFR: 39 ± 4 ml·min(-1)·1.73 m(-2)) and 10 healthy controls (55 ± 2 yr; 4 men/6 women; eGFR: >60 ml·min(-1)·1.73 m(-2)) were instrumented with 4 intradermal microdialysis fibers for the delivery of 1) Ringer solution (Control), 2) 10 μM tempol (scavenge superoxide), 3) 100 μM apocynin (NAD(P)H oxidase inhibition), and 4) 10 μM allopurinol (xanthine oxidase inhibition). Skin blood flow was measured via laser-Doppler flowmetry during standardized local heating (42°C). N(g)-nitro-l-arginine methyl ester (L-NAME; 10 mM) was infused to quantify the NO-dependent portion of the response. Cutaneous vascular conductance (CVC) was calculated as a percentage of the maximum CVC achieved during sodium nitroprusside infusion at 43°C. Cutaneous vasodilation was attenuated in patients with CKD (77 ± 3 vs. 88 ± 3%, P = 0.01), but augmented with tempol and apocynin (tempol: 88 ± 2 (P = 0.03), apocynin: 91 ± 2% (P = 0.001). The NO-dependent portion of the response was reduced in patients with CKD (41 ± 4 vs. 58 ± 2%, P = 0.04), but improved with tempol and apocynin (tempol: 58 ± 3 (P = 0.03), apocynin: 58 ± 4% (P = 0.03). Inhibition of xanthine oxidase did not alter cutaneous vasodilation in either group (P > 0.05). These data suggest that NAD(P)H oxidase is a source of reactive oxygen species and contributes to microvascular dysfunction in patients with CKD.

Keywords: cutaneous vasodilation; kidney disease; nitric oxide; oxidative stress.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Original recording of the skin blood flow response to local heating. Baseline measurements are made taken for ∼30 min at a local temperature of 33°C. An initial peak occurs upon increasing the local temperature to 42°C, followed by a sustained plateau that is primarily mediated by nitric oxide (NO). Once a stable plateau has been established, Ng-nitro-l-arginine methyl ester (l-NAME) is delivered through the microdialysis fiber to inhibit NO synthase (NOS). Following a stable post-l-NAME plateau, sodium nitroprusside is delivered through the fiber and the local temperature is increased to 43°C to cause a maximal dilation response.
Fig. 2.
Fig. 2.
Initial peak responses to tempol, apocynin, and allopurinol. Filled bars, healthy control (HC) responses; open bars, chronic kidney disease (CKD) responses. Values are means ± SE. *P < 0.05 vs. HC Ringer. †P < 0.05 vs. CKD Ringer.
Fig. 3.
Fig. 3.
Plateau responses and NO contribution. A: plateau responses in HC and CKD. B: post l-NAME plateau responses in HC and CKD. C: NO contribution in HC and CKD. Filled bars, HC responses; open bars, CKD responses. Values are means ± SE. *P < 0.05 vs. HC Ringer. †P < 0.05 vs. CKD Ringer.
Fig. 4.
Fig. 4.
Plasma asymmetric dimethylarginine (ADMA) and l-arginine levels. A: plasma ADMA levels. B: plasma l-arginine levels. C: l-arginine/ADMA ratio. Values are means ± SE. *P < 0.05 vs. HC.
See this image and copyright information in PMC

References

    1. Abularrage CJ, Sidawy AN, Aidinian G, Singh N, Weiswasser JM, Arora S. Evaluation of the microcirculation in vascular disease. J Vasc Surg 42: 574–581, 2005 - PubMed
    1. Annuk M, Lind L, Linde T, Fellstrom B. Impaired endothelium-dependent vasodilation in renal failure in humans. Nephrol Dial Transplant 16: 302–306, 2001 - PubMed
    1. Bai Y, Jabbari B, Ye S, Campese VM, Vaziri ND. Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. Am J Nephrol 29: 483–492, 2009 - PMC - PubMed
    1. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 356: 147–152, 2000 - PubMed
    1. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356: 1213–1218, 2007 - PubMed

Publication types

MeSH terms